Shares of San Diego-based Sequenom took a hit Feb. 3 after the company revised data on its Down syndrome test showing that its results were less effective than previously thought in identifying the condition in pregnant women.
Sequenom stock, traded under the symbol SQNM on Nasdaq, lost 7.2 percent to close at $18.90.
In previously reported data, Sequenom said its SEQureDx prenatal screening technology came up with one false positive result, meaning a woman could be told her unborn baby had Down syndrome when, in reality, it did not. That put its accuracy at 99.9 percent overall. Its latest data shows additional false positive results, amounting to 96.6 percent accuracy. Both times, its technology correctly identified 100 percent of the negative results.
Overall, the company has reported results in 858 women.
, Heather Chambers
